Novel vaccines and adjuvant systems: The utility of animal models for predicting immunogenicity in humans

Human Vaccines

Volumn 4, Issue 3, 2008, Pages 246-250

  Davis, Heather L ^a  

^a Coley Pharmaceutical Group ^*  (Canada)

Author keywords

Adjuvants; Animal models; Antigens; Immunogenicity; Vaccines

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTHRAX VACCINE; ANTIGEN; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; GLYCOPROTEIN GP 120; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; B LYMPHOCYTE; DATA ANALYSIS; DRUG ANTIGENICITY; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INBRED STRAIN; NONHUMAN; NOTE; PLASMODIUM FALCIPARUM; PREDICTION; SPECIES DIFFERENCE; T LYMPHOCYTE; VACCINE PRODUCTION; ANIMAL; ANIMAL MODEL; IMMUNOLOGY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; MODELS, ANIMAL; VACCINATION; VACCINES;

EID: 48249094543     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.3.5318     Document Type: Note

References (30)

1. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8. Science 2004; 303:1526-9.
2. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34:251-62.
3. O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003; 2:269-83.
4. Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun 2005; 73:828-33.
5. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18:1755-62.
6. Ioannou XP, Griebel P, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 2002; 76:9002-10.
7. Lopez AM, Hecker R, Mutwiri G, van Drunen Littel-van den Hurk, Babiuk LA, Townsend HG. Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine. Vet Immunol Immunopathol 2006; 114:103-10.
8. Tighe H, Takabayashi K, Schwartz D, Marsden R, Beck L, Corbeil J, Richman DD, Eiden JJ, Jr., Spiegelberg HL, Raz E. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000; 30:1939-47.
9. + T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005; 102:15190-4.
10. Najar HM, Dutz JP. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. Eur J Immunol 2007; 37:2242-56.
11. Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 2003; 2:253-67.
12. Freeh SA, Kenney RT, Spyr CA, Lazar H, Viret JF, Herzog C, Gluck R, Glenn GM. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005; 23:946-50.
13. Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, Grey H, Chesnut RW, Sette A. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997; 159:1383-92.
14. Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999; 30:531-6.
15. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B((R)) HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study. J Clin Immunol 2004; 24:693-701.
16. Kovarik J, Bozzotti P, Love Homan L, Pihlgren M, Davis HL, Lambert PH, Krieg AM, Siegrist CA. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol 1999; 162:1611-7.
17. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto, Smits W, Sajuthi DD. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000; 18:1920-4.
18. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. Aids 2005; 19:1473-9.
19. Klinman DM, Xie H, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann N Y Acad Sci 2006; 1082:137-50.
20. Rynkiewicz D, Rathkopf MM, Ransom M, Sim J, Giri I, Quinn L, Waytes T. Marked enhancement of Antibody Response to anthrax vaccine absorbed with CPG 7909 in healthy volunteers: 45th Interscience Conference on Antimicrobal Agents and Chemotherapy. Washington, DC: 2005.
21. Chatterjee S, Perignon JL, Van Marck E, Druilhe P. How reliable are models for malaria vaccine development? Lessons from irradiated sporozoite immunizations. J Postgrad Med 2006; 52:321-4.
22. Ott G, Radhakrishnan R, Fang JH, Hora M. The Adjuvant MF59: A 10-Year Perspective. In: O'Hagan DT, editor. Methods in Molecular Medicine. Totawa, New Jersey: Humana Press, Inc, 2000: 211-28.
23. Levy F, Colombetti S. Promises and limitations of murine models in the development of anticancer T-cell vaccines. Int Rev Immunol 2006; 25:269-95.
24. + T cell control of immunodeficiency virus infection in humans and macaques. Proc Natl Acad Sci USA 2007; 104:6365-70.
25. Garg R, Dube A. Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res 2006; 123:439-54.
26. Mullen GE, Giersing BK, Ajose Popoola O, Davis HL, Kothe C, Zhou H, Aebig J, Dobrescu G, Saul A, Long CA. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 2006; 24:2497-505.
27. Gu M, Hine PM, James JW, Giri L, Nabors GS. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 2007; 25:526-34.
28. Thoelen S, Van Damme P, Mathei C, Leroux Roels G, Desombere I, Safary A, Vandepapeliere P, Slaoui M, Meheus A. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16:708-14.
29. Heineman TC, Clements Mann ML, Poland GA, Jacobson RM, Izu AE, Sakamoto D, Eiden J, Van Nest GA, Hsu HH. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999; 17:2769-78.
30. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, Weeratna R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [published erratum appears in J Immunol 1999 ;162:3103]. J Immunol 1998; 160:870-6.